Prices are updated after-hours

Health Technology 2020 - 08 - 12

9 Meters Biopharma, Inc.

NMTR | $0.0722 -42.97% -67.9% 10M

(0.0% 1d) (0.0% 1m) (-93.1% 1y) (0.0% 2d) (0.0% 3d) (-43.0% 7d) (254.86% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 1,043,990
http://www.innovatebiopharma.com
Sec Filling | Patents | 8 employees

(US) 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

autoimmunity

add to watch list Paper trade email alert is off

Aerie Pharmaceuticals, Inc.

AERI | $15.25 0.0%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (13.48% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 753,615,457
http://www.aeriepharma.com
Sec Filling | Patents | 380 employees

(US) Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

eye treatment

Drugs

Rhopressa (netarsudil)
Rocklatan (netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%)

add to watch list Paper trade email alert is off

Eiger BioPharmaceuticals, Inc.

EIGR | $1.725 -1.45% 140K

Health Technology

(0.0% 1d) (-69.1% 1m) (72.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (16.88% volume)
Earnings Calendar: 2023-08-10
Market Cap: $ 2,554,375
http://www.eigerbio.com
Sec Filling | Patents | 24 employees

Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Drugs

Zokinvy (lonafarnib)

add to watch list Paper trade email alert is off

Endo International plc

ENDP | News | $0.2926 -9.6%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-5.0% 3d) (0.0% 7d) (97.63% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 68,802,809
http://www.endo.com
Sec Filling | Patents | 3172 employees

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.

cardiovascular women health nervous system women brands msa injection

add to watch list Paper trade email alert is off

Entasis Therapeutics Holdings Inc.

ETTX | $2.19 -0.46% 0.46%

Health Technology

(0.0% 1d) (-0.2% 1m) (0.0% 1y) (-0.2% 2d) (0.2% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-08-03
Market Cap: $ 104,795,396
http://www.entasistx.com
Sec Filling | Patents | 47 employees

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.

batteries battery msa antibacterial injection

add to watch list Paper trade email alert is off

Brickell Biotech, Inc.

BBI | $2.12 16.04%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-74.2% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 6,092,806
http://www.brickellbio.com
Sec Filling | Patents | 15 employees

(US) Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

dermatitis skin t-cell treatment ceiling

add to watch list Paper trade email alert is off

Apollo Endosurgery, Inc.

APEN | $10.0 0.75% 1.7M

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-53.84% volume)
Earnings Calendar: 2023-05-02
Market Cap: $ 579,719,190
http://apolloendo.com
Sec Filling | Patents | 217 employees

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, OverStitch Sx Endoscopic Suturing System, and Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon; the treatment of swallowing disorders; esophageal stent fixation and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

gastrointestinal endoscopy treatment

add to watch list Paper trade email alert is off

Checkmate Pharmaceuticals, Inc.

CMPI | $10.5 0.0%

Health Technology

(0.0% 1d) (0.2% 1m) (0.0% 1y) (0.2% 2d) (0.1% 3d) (0.0% 7d) (-49.8% volume)
Earnings Calendar: 2022-08-11
Market Cap:
http://www.checkmatepharma.com
Sec Filling | Patents | 22 employees

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.

cancer

add to watch list Paper trade email alert is off

Athenex, Inc.

ATNX | $0.2031 -7.78% 1.9M

Health Technology

(0.0% 1d) (0.0% 1m) (-82.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (199.02% volume)
Earnings Calendar: 2022-10-27
Market Cap: $ 1,759,498
http://www.athenex.com
Sec Filling | Patents | 574 employees

(US) Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

cancer tirbanibulin treatment

add to watch list Paper trade email alert is off

Ayala Pharmaceuticals, Inc.

AYLA | $0.5036 5.84% -0.7% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (15.3% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 7,463,718
http://www.ayalapharma.com
Sec Filling | Patents | 29 employees

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. It is focused on the development and commercialization of small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel.

cancer israel diagnostics

add to watch list Paper trade email alert is off

Meridian Bioscience Inc.

VIVO | $33.97 0.0% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.7% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-02-03
Market Cap: $ 1,488,831,011
http://www.meridianbioscience.com
Sec Filling | Patents | 750 employees

(US) Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the following segments: Diagnostics and Life Science. The Diagnostics segment consists testing platforms and technologies such as Isothermal DNA Amplification, Rapid Immunoassay, Enzyme-linked Immunoassay, and Anodic Stripping Voltammetry. The Life Science segment distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

antibody t-cell diagnostics ceiling

add to watch list Paper trade email alert is off

Neovasc Inc.

NVCN | $30.03 1.66% -2.02% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (615.5% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 81,306,886
http://www.neovasc.com
Sec Filling | Patents | 110 employees

(CA) Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. Its focuses on Neovast Tiara, and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

education cosira-ii heart

add to watch list Paper trade email alert is off

Oyster Point Pharma, Inc.

OYST | $11.17 0.18% -0.27%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (583.77% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 299,850,742
http://www.oysterpointrx.com
Sec Filling | Patents | 17 employees

Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.

eye diseases eye ocular msa 3d

add to watch list Paper trade email alert is off

Humanigen, Inc.

HGEN | $0.0361 -61.5% 120M

Health Technology

(0.0% 1d) (0.0% 1m) (-78.1% 1y) (0.0% 2d) (0.0% 3d) (-81.1% 7d) (23283.32% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 4,298,793
http://www.humanigen.com
Sec Filling | Patents | 2 employees

(US) Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

cancer gene therapies t-cell treatment ceiling

add to watch list Paper trade email alert is off

IMV Inc.

IMV | $0.8225 -2.74% 45K

Health Technology

(0.0% 1d) (0.0% 1m) (1.5% 1y) (-2.5% 2d) (-2.5% 3d) (0.0% 7d) (-76.64% volume)
Earnings Calendar: 2023-05-12
Market Cap: $ 9,632,821
http://www.imv-inc.com
Sec Filling | Patents | n/a employees

IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.

vaccine covid cancer ovarian cancer immunotherapy infectious disease glass t-cell ceiling

add to watch list Paper trade email alert is off

Onconova Therapeutics, Inc.

ONTX | $0.9953 -5.61% 1.3M

Health Technology

(0.0% 1d) (13.6% 1m) (-15.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-87.86% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 20,904,693
http://www.onconova.com
Sec Filling | Patents | 19 employees

(US) Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

cancer molecule drugs

add to watch list Paper trade email alert is off

Surgalign Holdings, Inc.

SRGA | $0.1829 -50.36% 8.7M

Health Technology

(0.0% 1d) (0.0% 1m) (-74.3% 1y) (0.0% 2d) (-9.1% 3d) (0.0% 7d) (-54.59% volume)
Earnings Calendar: 2023-08-08
Market Cap: $ 1,690,130
http://www.surgalign.com
Sec Filling | Patents | 935 employees

Surgalign Holdings, Inc. is a global medical technology company, which engages in designing, developing and manufacturing biologic metal and synthetic implants worldwide. It focuses on delivering spine solutions that drive clinical and economic outcomes. The company markets its products throughout the United States and other countries worldwide through an expanding network of independent distributors. The company was founded in February 1998 and is headquartered in Deerfield, IL.

add to watch list Paper trade email alert is off

TCR2 Therapeutics Inc.

TCRR 4 | $1.48 3.38% 3.9M

Health Technology

(0.0% 1d) (0.0% 1m) (-16.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (906.93% volume)
Earnings Calendar: 2023-08-07
Market Cap: $ 58,107,383
http://www.tcr2.com
Sec Filling | Patents | 83 employees

(US) TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. The firm offers cancer therapy, t-cell biology, immunology and molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of t-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.

cancer immunotherapy immunology t-cell ceiling

add to watch list Paper trade email alert is off

Titan Medical Inc.

TMDI | News | $0.14 -26.32% -35.52% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-25.3% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-08-10
Market Cap: $ 15,673,600
http://www.titanmedicalinc.com
Sec Filling | Patents | 10 employees

(CA) Titan Medical, Inc. engages in the research and development of SPORT Surgical System, a computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS) comprising single-port robotic surgical system. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada.

computational

add to watch list Paper trade email alert is off

Tyme Technologies, Inc.

TYME | $0.3107 -8.21%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (8.1% 2d) (18.4% 3d) (0.0% 7d) (-9.91% volume)
Earnings Calendar:
Market Cap: $ 53,504,682
http://www.tymeinc.com
Sec Filling | Patents | 18 employees

(United States) Tyme Technologies, Inc. is a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.

cancer t-cell ceiling

add to watch list Paper trade email alert is off